Takeda Pharmaceutical Company Limited (TKPHF)

28.06 0.00 (0.00%) At close: 02:19PM EST

Takeda Pharmaceutical Company Limited

1-1, Nihonbashi-Honcho 2-chome
Chuo-ku
Tokyo 103-8668
Japan
81 3 3278 2111
https://www.takeda.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 49,095

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Christophe Weber	President, CEO & Representative Director	3.96M	N/A	1966
Mr. Constantine Saroukos	CFO & Representative Director	2.47M	N/A	1971
Dr. Andrew S. Plump	President of Research & Development and Representative Director	2.83M	N/A	1965
Dr. Seigo Izumo	Chair of Management Board	N/A	N/A	N/A
Mr. Haruhiko Hirate	Member of Management Board	N/A	N/A	1957
Mr. Salvatore Alesci M.D., Ph.D.	Member of Management Board and Head of R&D Global Science & Biomedical Policy	N/A	N/A	1974
Norimasa Takeda	Chief Accounting Officer & Corporate Controller	N/A	N/A	N/A
Mr. Iwaaki Taniguchi	Senior Vice President of Corporate Finance & Controlling Department	N/A	N/A	N/A
Mr. Gabriele Ricci	Chief Data & Technology Officer	N/A	N/A	1978
Mr. Christopher David O'Reilly	Global Head of Investor Relations & Global Finance	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, JCR Pharmaceuticals, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Corporate governance

Takeda Pharmaceutical Company Limited’s ISS governance QualityScore as of 1 December 2023 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 5; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.